Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP...

Full description

Bibliographic Details
Main Authors: Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-09-01
Series:JCI Insight
Subjects:
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.140532

Internet

https://doi.org/10.1172/jci.insight.140532

Similar Items